Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Rhea-AI Summary

Context Therapeutics (Nasdaq:CNTX), a clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors, has been added to the Russell 2000 and Russell 3000 indexes.

Inclusion became effective after U.S. market close on June 26, 2026, aligning CNTX with widely used U.S. equity benchmarks.

Positive

• Added to Russell 2000 and Russell 3000 indexes, effective June 26, 2026

Negative

• None.

News Market Reaction – CNTX

+9.79%

12 alerts

+9.79% Session close to close

+5.6% Peak in 6 hr

$60.06M Market Cap

0.5x Rel. Volume

In the Jul 7 session, CNTX gained 9.79%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +9.8% in the session following this news. A strong gain following inclusion in major...

Analysis

The stock moved +9.8% in the session following this news. A strong gain following inclusion in major Russell indexes would mark a contrast to the -51.53% reaction to positive Phase 1 data, suggesting investors increasingly value index-driven visibility while low short interest tempers short-squeeze risk.

Key Figures

Companies in Russell 3000: 3,000 companies U.S. equity coverage: 98% of investable market

2 metrics

Companies in Russell 3000 3,000 companies Constituents measured by the Russell 3000 Index

U.S. equity coverage 98% of investable market Portion of investable U.S. equity market represented by Russell 3000 Index

Historical Context

5 past events · Latest: Jun 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 15	Phase 1 data	Positive	-51.5%	Reported positive interim Phase 1a efficacy and safety data for CTIM-76 in PROC.
Jun 09	Inducement grant	Negative	-4.6%	Granted employee stock options under Nasdaq Rule 5635(c)(4) at a set exercise price.
May 27	Conference presentation	Positive	+13.3%	Announced presentation at Jefferies Global Healthcare Conference plus an inducement option grant.
May 18	License amendment	Positive	-0.5%	Amended BioAtla CT-202 license, eliminating future milestones and royalties for fixed payments.
May 06	Q1 2026 earnings	Neutral	-3.3%	Reported Q1 2026 financials, cash runway into mid-2027, and upcoming clinical milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has produced mixed reactions, with some positive catalysts followed by sharp downside moves, indicating inconsistent trading responses to company developments.

Key Terms

t cell engaging, bispecific antibodies, index funds, small-cap

4 terms

t cell engaging medical

"a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific"

T cell engaging describes a type of immunotherapy that directs a patient’s T cells—immune cells that kill infected or abnormal cells—to recognize and attack disease cells by physically linking or activating them, like a matchmaker bringing two parties together to get a job done. Investors monitor these therapies because they can offer strong, targeted clinical effects and commercial upside, but they also involve safety risks, complex manufacturing and tight regulatory review that influence development timelines and returns.

bispecific antibodies medical

"advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors"

Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.

index funds financial

"used by investment managers and institutional managers for index funds and as benchmarks"

A fund that pools investors’ money to buy the same collection of stocks or bonds that make up a market index — like a ready-made basket representing the whole market or a specific slice of it. It matters because it gives broad exposure with lower fees and simpler management than picking individual securities, reducing the impact of any single holding and making it efficient for long-term investing.

small-cap financial

"added to the small-cap Russell 2000® and the broad-market Russell 3000® Indexes"

Small-cap describes publicly traded companies with a relatively low total market value, measured by multiplying their share price by the number of shares outstanding — think of them as smaller boats in a large investment fleet. They matter to investors because they often offer greater growth potential than bigger firms but also come with higher price swings, lower trading volume, and therefore greater risk and potential difficulty buying or selling shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000^® and the broad-market Russell 3000^® Indexes, effective at the close of U.S. equity markets on June 26, 2026.

The Russell 3000^® Index measures the performance of the largest 3,000 publicly traded U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell 2000^® Index is a subset of the Russell 3000^® Index and serves as the leading benchmark for U.S. small-cap equities. The Russell Indexes are used by investment managers and institutional managers for index funds and as benchmarks for active investment strategies.

For more information on the Russell Indexes and the semi-annual reconstitution process, visit the “Russell Reconstitution” section on the FTSE Russell website.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s strategy, future operations, prospects, and plans and objectives of management, are forward-looking statements. These statements may be identified by words such as “may,” “will,” “expect,” “believe,” “could,” “estimate,” “potential,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions.

These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied, and the Company cannot assure that its plans, intentions, expectations, or strategies will be achieved. These risks and uncertainties include, without limitation: (i) uncertainties regarding the Company’s expectations, projections, and estimates of future costs and expenses, capital requirements, the availability of additional financing and the Company’s capital requirements; (ii) the timing, progress, and results of the Company’s discovery, preclinical and clinical development activities; (iii) clinical trial site activation and enrollment; (iv) unexpected safety or efficacy data observed during preclinical studies or clinical trials; (v) the risk that results from nonclinical or clinical studies may not be predictive of future results, and that interim data are subject to further analysis; (vi) uncertainties related to the regulatory approval process; (vii) the Company’s reliance on third parties; (viii) macroeconomic conditions; and (ix) whether the Company has sufficient funding to meet future operating expenses and capital expenditure requirements. Additional factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including future reports.

Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, which speak only as of the date of this press release, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

What did Context Therapeutics (CNTX) announce about the Russell indexes on July 6, 2026?

Context Therapeutics announced its inclusion in the Russell 2000 and Russell 3000 indexes. According to Context Therapeutics, the additions became effective at the close of U.S. equity markets on June 26, 2026, aligning CNTX with major U.S. equity benchmarks.

When did Context Therapeutics (NASDAQ:CNTX) join the Russell 2000 and Russell 3000 indexes?

Context Therapeutics joined the Russell 2000 and Russell 3000 indexes effective June 26, 2026. According to Context Therapeutics, the inclusion took effect at the close of U.S. equity markets as part of FTSE Russell’s index reconstitution process for U.S. companies.

What are the Russell 2000 and Russell 3000 indexes that now include Context Therapeutics (CNTX)?

The Russell 3000 index tracks the largest 3,000 U.S. public companies, while the Russell 2000 is its small-cap subset. According to FTSE Russell, these benchmarks cover about 98% of the investable U.S. equity market and guide many index and active strategies.

Why is inclusion in the Russell 2000 important for Context Therapeutics (CNTX) shareholders?

Inclusion places Context Therapeutics within a leading small-cap U.S. equity benchmark. According to FTSE Russell, the Russell 2000 and related indexes are widely used by investment managers for index funds and as performance benchmarks, potentially increasing institutional attention to member companies.

What type of company is Context Therapeutics, now added to the Russell indexes under ticker CNTX?

Context Therapeutics is a clinical-stage biopharmaceutical company. According to Context Therapeutics, it focuses on advancing T cell engaging bispecific antibodies designed to treat solid tumors, positioning CNTX within the healthcare segment of the Russell 2000 and Russell 3000 indexes.